179419-11-5

Basic information

• Product Name: 5-Bromonaphthalene-2-sulfonic acid
• Synonyms: 5-Bromonaphthalene-2-sulfonic acid
• CAS NO: 179419-11-5
• Molecular Formula: C10H7BrO3S
• Molecular Weight: 287.12978
• Mol File: 179419-11-5.mol

Chemical Properties

• Appearance: /
• Density: 1.766±0.06 g/cm3(Predicted)
• PKA: 0.05±0.40(Predicted)
• CAS DataBase Reference: 5-Bromonaphthalene-2-sulfonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromonaphthalene-2-sulfonic acid(179419-11-5)
• EPA Substance Registry System: 5-Bromonaphthalene-2-sulfonic acid(179419-11-5)

Safety Data

• Hazardous Substances Data: 179419-11-5(Hazardous Substances Data)

Upstream product

• 179419-12-6 neopentyl 5-bromonaphthalene-2-sulfonate 
• 120-18-3 naphthalene-2-sulfonate 
• 119-79-9 5-aminonaphthalene-2-sulfonic acid 
• 127769-55-5 5-bromo-2-naphthalenesulfonic acid chloride 

Relevant articles and documents

Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics to Enable in Vivo Target Engagement

Human genetic evidence has identified the voltage-gated sodium channel NaV1.7 as an attractive target for the treatment of pain. We initially identified naphthalene sulfonamide 3 as a potent and selective inhibitor of NaV1.7. Optimization to reduce biliary clearance by balancing hydrophilicity and hydrophobicity (Log D) while maintaining NaV1.7 potency led to the identification of quinazoline 16 (AM-2099). Compound 16 demonstrated a favorable pharmacokinetic profile in rat and dog and demonstrated dose-dependent reduction of histamine-induced scratching bouts in a mouse behavioral model following oral dosing.

Compound for inhibiting HIV infectivity

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.

Sulfonic acid and aldehyde condensation polymers for preventing pregnancy

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalenesulfonic acid condensation polymers, can prevent pregnancy in an individual.

Compound for inhibiting HIV infectivity

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalene-sulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.

Compound for inhibiting HIV infectivity

This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalene-sulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.

Neopentyl ester protecting groups for arylsulfonic acids

We report that neopentylsulfonate esters are stable to a variety of standard organic reaction conditions and are easily cleaved to sulfonic acids. We also discuss the use of N-Boc-4-amino-2,2-dimethylbutyl-1-sulfonate esters which may be cleaved under conditions that are suitable for solid phase synthesis.